Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter

February 27, 2018 Cyrcadia, Inc. (“CI”) extends its thanks and appreciation in your interest and support of our endeavors. We are taking this opportunity to provide an update, as well as apprise you of upcoming expectations. License and Cooperation Agreement with Cyrcadia Asia (“CA”) – Status Earlier in 2017 CI entered into an Agreement with CA, whereby CA assumed the responsibility and funding of the design, development and delivery of a scalable, commercializable iTBra™ system including upgraded hardware and the full suite of application software as well as automation of our proprietary Artificial Intelligence Analytics. The estimated cost of development with Jabil and Mobile Now is approximately $1.2 to $1.5 million US. As such, the agreement calls for CA to provide timely reporting and status of product development including timelines, milestones and dates of completion and delivery of product (market readiness, product volume availability and delivery terms and schedules). Many strides have been made in the evolution of the relationship as CA has established its operations, initial staffing and funding. Both CI and CA are in a mode of cooperation, as called for by the Agreement and, presently, both entities are to hold routine meetings where comprehensive updating and reporting will be delivered to CI, enabling implementation of our business, operations and marketing plans. We will be reporting the outcomes of that meeting to move forward on our ability to commercialize the iTBra™ system this year. Given the above, we would like to update on the internal operations that will allow for CI to “hit the ground running” upon product delivery. Status of Product Development and Manufacturing Under CA’s...

Cyrcadia, Inc. Wins Prestigious Cannes Lions Awards

Cyrcadia, Inc. (CI) announced it has won two prestigious awards at the Cannes Lions International Festival of Creativity, a global event for the creative communications, marketing and advertising world. Held in Cannes, France and attended by over 10,000 delegates, Lion awards are considered the most coveted in the industry. The first award was a Bronze Lion in the category of Innovation, which honors ground-breaking technology and problem-solving. It specifically looks at how technology, data and ideas, when working in unison, can revolutionize lives. Cyrcadia shared the Bronze award with industry giants such as Google, Shell and Apple. The second award was a Silver Glass Lion award, recognizing ideas that could change the world and positively impact gender inequality or injustice. Cyrcadia’s ability to deliver early breast cancer health monitoring to the mass populations of women who have little or no access to quality health care was key to Cyrcadia’s award achievement. Cyrcadia is developing and marketing a device and software that monitors for biometric changes that correlate to breast cancer . Known as the iTBra, the device is based on wearable sensor patches that are placed under a woman’s own garments and worn for two hours. The sensor data results processed through Cyrcadia’s artificial intelligence (AI) lab can be automatically communicated to the patient, her physician and insurance company. Based on Cyrcadia’s monitoring device, a patient will be recommended for further investigation by a physician. The company’s technology has obtained U.S. FDA 510(k) Class II clearance. While the technology is based on historic data from a trial of 200 patients, recent validation trials on 46 patients have confirmed prior...

Lifeline announces transfer of breast cancer detection technology to subsidiary

Reno-based Lifeline Biotechnologies, Inc. (OTC PINK: LLBO) recently transferred breast cancer detection technology to Cyrcadia, Inc. in exchange for 4,670,000 shares of Cyrcadia, Inc. common stock and a $110,000 cash and $220,000 promissory note. The additional 4,670,000 shares added to Lifeline’s original 8,000,000 shares totals 12,670,000 shares. Lifeline’s ownership is increased to over 45 percent of Cyrcadia, Inc., making Lifeline Cyrcadia, Inc.’s largest single shareholder. The technology transfer enabled Cyrcadia, Inc. to license Cyrcadia Asia Limited for the marketing of Cyrcadia, Inc. products throughout the Asian markets. Rob Royea, Cyrcadia, Inc.’s former CEO, is moving to Hong Kong to manage the Asian opportunity, representing a population of 1.8 billion people. Cyrcadia, Inc. received the following compensation for the license to Cyrcadia Asia Limited: An $830,000 Cyrcadia, Inc. equity investment at $1.00 per share with an equal $1.00 warrant; a $1,050,000 promissory note; Cyrcadia Asia, Limited assumed approximately $3,000,000 in product development costs for the Bluetooth and added sensor costs. Cyrcadia, Inc. received an equity interest in Cyrcadia Asia, Limited. Additionally, Cyrcadia Asia Limited assumed approximately $500,000 of Cyracdia, Inc.’s annual general and administrative expenses. Cyrcadia Asia Limited will license Cyrcadia, Inc. for the developed Bluetooth and additional sensors products once development is completed. The transaction is valued at approximately $5 million. The Bluetooth capabilities will enable patient data to be transmitted directly, over the Internet, to the testing physician, and/or the data interpretation center. The added sensors will enable the systems to exactly locate the tissue abnormality or cancer within the breast tissue. By locating the abnormality, the physician performing the biopsy will know exactly where the probe should be inserted into the tissue. Cyrcadia, Inc., a Nevada corporation, founded by...

Cyrcadia, Inc. Prepares for iTBra™ Product Launch and Expands Strategic Operations to Asia

Cyrcadia, Inc.(CI) announced this week a strategic expansion to accelerate operations and market launch into Asia for early breast cancer monitoring. CI has entered into a License and Cooperation Agreement Cyrcadia Asia, Ltd. (CA), a newly formed company in Hong Kong which will serve as the base for the Asia market launch of CI’s proprietary iTBraTM technology expected to commence in late 2017 or early 2018 under the global CI brand of Cyrcadia Health. Under the License and Cooperation Agreement, Cyrcadia Asia has exclusive marketing rights to the iTBra technology and products in Asia. CA will assume and fund certain further product development and other activities with respect to the iTBra technology and products for the benefit of both CI and CA. The License and Cooperation Agreement also provides for certain other financial terms between the two parties intended to enable the launch of the technology and products in Asia. CI retains exclusive marketing rights to the United States, Mexico and Canada, with the marketing strategy for the iTBra technology and products in other countries to be further discussed by the parties. Having obtained U.S. FDA 510(k) Class II approval for its iTBra technology, CI has conducted clinical trials in the U.S. with its newly developed scalable product, which demonstrates greatly improved outcomes, beyond historical product results. CI’s predictive analytic artificial intelligence (AI) based technology now demonstrates 80%+ accuracy with a two-hour wear when compared with the original trials which required 48-hour wear and achieved 74% accuracy. CI and CA expect this greatly improved performance to support the use of the 510(k) approval to launch the technology and products...

Early Detection – Nedra

The opportunity of early detection and management of breast tissue abnormalities is a reality and has already made significant impacts in many lives. Nedra’s story is just one of those. Please take a moment to hear about the impact of the Cyrcadia Health technology in Nedra’s life, along with support and thoughts of the primary investigator of this particular study, Dr. Ronald...